donepezil has been researched along with Hyperhomocysteinemia in 3 studies
Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.
donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.
Hyperhomocysteinemia: Condition in which the plasma levels of homocysteine and related metabolites are elevated (
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present study investigates the effect of ozagrel, a selective thromboxane A2 (TXA2) inhibitor, in rat model of hyperhomocysteinemia (HHcy)-induced vascular cognitive impairment and dementia (VCID)." | 8.02 | Ameliorative effect of ozagrel, a thromboxane A2 synthase inhibitor, in hyperhomocysteinemia-induced experimental vascular cognitive impairment and dementia. ( Bhatia, P; Singh, N, 2021) |
| "This study was designed to investigate the effects of fisetin (FST) on hyperhomocysteinemia (HHcy)-induced experimental endothelial dysfunction (ED) and vascular dementia (VaD) in rats." | 7.85 | Effects of fisetin on hyperhomocysteinemia-induced experimental endothelial dysfunction and vascular dementia. ( Arun Reddy, R; Dinesh Kumar, B; Diwan, PV; Hemanth Kumar, B; Mahesh Kumar, J, 2017) |
| " In this study, we tested the effects of a synthesized juxtaposition (named SCR1693) composed of an acetylcholinesterase inhibitor (AChEI) and a calcium channel blocker (CCB) on the hyperhomocysteinemia (HHcy)-induced AD rat model, and found that SCR1693 remarkably improved the HHcy-induced memory deficits and preserved dendrite morphologies as well as spine density by upregulating synapse-associated proteins PSD95 and synapsin-1." | 7.80 | Novel multipotent AChEI-CCB attenuates hyperhomocysteinemia-induced memory deficits and Neuropathologies in rats. ( Chen, R; Hu, J; Liu, R; Liu, X; Tian, Q; Wang, JZ; Wang, P; Wang, Q; Wang, XC; Xia, Y; Zeng, K, 2014) |
| "The present study investigates the effect of ozagrel, a selective thromboxane A2 (TXA2) inhibitor, in rat model of hyperhomocysteinemia (HHcy)-induced vascular cognitive impairment and dementia (VCID)." | 4.02 | Ameliorative effect of ozagrel, a thromboxane A2 synthase inhibitor, in hyperhomocysteinemia-induced experimental vascular cognitive impairment and dementia. ( Bhatia, P; Singh, N, 2021) |
| "This study was designed to investigate the effects of fisetin (FST) on hyperhomocysteinemia (HHcy)-induced experimental endothelial dysfunction (ED) and vascular dementia (VaD) in rats." | 3.85 | Effects of fisetin on hyperhomocysteinemia-induced experimental endothelial dysfunction and vascular dementia. ( Arun Reddy, R; Dinesh Kumar, B; Diwan, PV; Hemanth Kumar, B; Mahesh Kumar, J, 2017) |
| " In this study, we tested the effects of a synthesized juxtaposition (named SCR1693) composed of an acetylcholinesterase inhibitor (AChEI) and a calcium channel blocker (CCB) on the hyperhomocysteinemia (HHcy)-induced AD rat model, and found that SCR1693 remarkably improved the HHcy-induced memory deficits and preserved dendrite morphologies as well as spine density by upregulating synapse-associated proteins PSD95 and synapsin-1." | 3.80 | Novel multipotent AChEI-CCB attenuates hyperhomocysteinemia-induced memory deficits and Neuropathologies in rats. ( Chen, R; Hu, J; Liu, R; Liu, X; Tian, Q; Wang, JZ; Wang, P; Wang, Q; Wang, XC; Xia, Y; Zeng, K, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bhatia, P | 1 |
| Singh, N | 1 |
| Xia, Y | 1 |
| Liu, R | 1 |
| Chen, R | 1 |
| Tian, Q | 1 |
| Zeng, K | 1 |
| Hu, J | 1 |
| Liu, X | 1 |
| Wang, Q | 1 |
| Wang, P | 1 |
| Wang, XC | 1 |
| Wang, JZ | 1 |
| Hemanth Kumar, B | 1 |
| Arun Reddy, R | 1 |
| Mahesh Kumar, J | 1 |
| Dinesh Kumar, B | 1 |
| Diwan, PV | 1 |
3 other studies available for donepezil and Hyperhomocysteinemia
| Article | Year |
|---|---|
Ameliorative effect of ozagrel, a thromboxane A2 synthase inhibitor, in hyperhomocysteinemia-induced experimental vascular cognitive impairment and dementia.
Topics: Animals; Dementia, Vascular; Donepezil; Endothelium, Vascular; Enzyme Inhibitors; Female; Hyperhomoc | 2021 |
Novel multipotent AChEI-CCB attenuates hyperhomocysteinemia-induced memory deficits and Neuropathologies in rats.
Topics: Animals; Brain Diseases; Calcium Channel Blockers; Cholinesterase Inhibitors; Disease Models, Animal | 2014 |
Effects of fisetin on hyperhomocysteinemia-induced experimental endothelial dysfunction and vascular dementia.
Topics: Acetylcholinesterase; Animals; Aorta; Brain; Catalase; Cholesterol; Dementia, Vascular; Donepezil; D | 2017 |